Press Releases

Global and regional licensing agreements will extend Crocs brand to accessories, apparel and eyewear

NIWOT, Colo.--(BUSINESS WIRE)-- Crocs, Inc. (NASDAQ: CROX) today announced its expansion into licensing, providing opportunities for the Crocs brand to extend beyond footwear. The company has signed licensing agreements with key global and regional manufacturers for products ranging from apparel to sunglasses and other accessories.

“Licensing presents an opportunity to leverage one of our most valuable assets – the global power of the Crocs brand - by associating it with best-in-class products that go beyond footwear,” said Mike DeBell, Vice President of Global Sales. “More than 200 million pairs of Crocs shoes have been sold, in more than 90 countries around the world. That’s powerful testimony to the connection forged with consumers by the Crocs brand. Through strong international and regional licensing partners, we plan to extend the power of our brand and make new consumer connections.”

The first non-footwear Crocs-branded products included a line of adult and children’s socks from Sock and Accessories Brands, which launched in the holiday 2011 season. These are available in North America through wholesale and retail channels. Crocs-branded socks, produced by Intersocks, will also be available throughout European markets.

Crocs also entered an agreement with Accessory Exchange, which is producing a variety of Crocs-branded accessories for men, women and children, in several global regions. Accessory Exchange Crocs-branded products include hats, bags, backpacks, socks and gloves that are available now at Crocs retail stores and Crocs.com.

In April 2012, the Crocs brand will extend to children’s apparel through an agreement with the A Group. The children’s apparel will be available in 46 countries around the globe and distributed through retail and wholesale channels. Crocs-branded sunglasses and sunglass accessories also will launch in May 2012. Eye King, LLC is producing sunglasses for adults and youth for retail and wholesale distribution in the U.S. and Canada.

Through a partnership with ICER Brands, Crocs Professional Footwear Division will build on the loyal following of medical professionals with the introduction of Crocs-branded scrubs. This new medical gear is available now through specialty stores and online.

Finally, Paramount, a sports licensee, recently kicked off Collegiate and MLB licensed footwear for the brand, which is available now.

“As we continue to explore these and other new collaborations, I am confident our license partners will help us grow and spread our brand promise of delivering products with profound comfort, fun and innovation,” continued DeBell.

More information about Crocs is available at www.crocs.com.

About Crocs, Inc.

A world leader in innovative casual footwear for men, women and children, Crocs, Inc. (NASDAQ: CROX), offers several distinct shoe collections with more than 250 styles to suit every lifestyle. As lighthearted as they are lightweight, Crocs™ footwear provides profound comfort and support for any occasion and every season. All Crocs™ branded shoes feature Croslite™ material, a proprietary, revolutionary technology that produces soft, non-marking, and odor-resistant shoes that conform to your feet.

Crocs™ products are sold in 90 countries. Every day, millions of Crocs™ shoe lovers around the world enjoy the exceptional form, function, versatility and feel-good qualities of these shoes while at work, school and play.

Visit www.crocs.com for additional information.

Crocs, Inc.Shelley Weibel, 303-848-7000sweibel@crocs.com

Source: Crocs

CORAL GABLES, Fla., Feb. 9, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) announced today that it has filed a provisional patent application with the United States Patent and Trademark Office for the use of GABA aminotransferase inhibitors, including CPP-109 and CPP-115, in the treatment of Tourette Syndrome. Catalyst, one of the inventors, through a license agreement with the co-inventors' respective institutions, has exclusive worldwide rights to GABA aminotransferase inhibitors for this use.

Catalyst's intellectual property is a method of treating Tourette Syndrome using GABA aminotransferase inhibitor drugs, including CPP-109 and CPP-115, which significantly increase presynaptically stored GABA, and enhance GABA signaling in the striatal-thalamo-cortical tracts involved in habit formation and motor control.

Catalyst has agreed to provide drug product and financial support for a proof-of-concept study at a prestigious academic institution in the United States. This study will evaluate the use of CPP-109 in treating Tourette Syndrome, and is expected to take approximately one year to complete.

"The filing of this provisional patent application represents another important step forward in advancing and maximizing the value of Catalyst's GABA aminotransferase inhibitor platform for the benefit of our patients and shareholders," said Patrick J. McEnany, Chief Executive Officer of Catalyst. "Our goal is to build a leading central nervous system (CNS) specialty pharmaceutical company focused on developing drugs to address unmet medical needs and orphan diseases. The use of CPP-109 and CPP-115 in the treatment of Tourette Syndrome may provide us with significant CNS expansion opportunities while addressing an important medical need."

About Tourette Syndrome

Tourette Syndrome is a neurobiological disorder characterized by multiple motor and vocal tics that are associated with considerable disability and reduction in quality of life. The tics are often involuntary, rapid, sudden movements and/or vocal outbursts that occur repeatedly. No definite cause has been established for Tourette Syndrome, although considerable evidence points to abnormal metabolism of dopamine in the brain. The majority of clinically referred youth with Tourette Syndrome meet the criteria for comorbid obsessive-compulsive disorder (OCD) and attention deficit hyperactivity disorder (ADHD), while young adults meet the criteria for additional anxiety, mood and substance abuse disorders. It is estimated that approximately 200,000 people are affected by the most severe form of Tourette Syndrome in the United States, often leading the FDA to grant orphan drug designation for such product candidates to treat this disorder. There is no cure for Tourette Syndrome and the only approved products for treatment are haloperidol and pimozide, with both having limited efficacy and significant side effects.

About Catalyst Pharmaceutical Partners, Inc.

Catalyst Pharmaceutical Partners, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system. Catalyst has two products in development, and is currently evaluating its lead product and first-in-class GABA aminotransferase inhibitor candidate, CPP-109 (vigabatrin), for the treatment of cocaine dependency. CPP-109 has been granted "Fast Track" status by the U.S. Food & Drug Administration (FDA) for the treatment of cocaine dependency. Catalyst also expects to evaluate CPP-109 for the treatment of other addictions and OCDs. Catalyst is also developing CPP-115, a next-generation GABA aminotransferase inhibitor, which is more potent than vigabatrin and potentially has reduced side effects (e.g., visual field defects, or VFDs) from those associated with vigabatrin. Catalyst is planning to develop CPP-115 for several indications, including drug addiction, epilepsy (initially infantile spasms) and for other selected CNS indications. CPP-115 has been designated as a "Fast Track" development program for the treatment of cocaine dependency and has been granted orphan drug designation for the treatment of infantile spasms, both by the FDA. Catalyst believes that it controls all current intellectual property for drugs that have a mechanism of action related to the inhibition of GABA aminotransferase. For more information about Catalyst, go to www.catalystpharma.com.

Forward Looking Statements

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from forecasted results. A number of factors, including whether CPP-109 will be determined to be effective in the treatment of Tourette Syndrome, whether CPP-109 or CPP-115 will ever be approved for commercialization, and those other factors described in the Company's filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect the Company. Copies of the Company's filings with the SEC are available from the SEC, may be found on the Company's website or may be obtained upon request from the Company. The Company does not undertake any obligation to update the information contained herein, which speaks only as of this date.

CONTACT: Patrick J. McEnany
         Catalyst Pharmaceutical Partners
         Chief Executive Officer
         (305) 529-2522
         pmcenany@catalystpharma.com

         Melody Carey
         Rx Communications Group
         Co-President
         (917) 322-2571
         mcarey@rxir.com

Dynamic LED lighting industry leader joins Intematix executive team to drive market growth for phosphor based products

FREMONT, Calif.--(BUSINESS WIRE)-- Intematix, a leading innovator of patented phosphors and phosphor components for high-quality LED lighting, today announced Steve Barlow as the company’s Chief Commercial Officer. Most recently, Barlow served as Executive Vice President of Sales and Marketing at Philips Lumileds where he built LED lighting into a global phenomenon. Barlow will direct Intematix’s commercial strategy and development as the company scales operations for its phosphor and ChromaLit™ remote phosphor lighting products.

“Steve Barlow’s experience and vision are assets toward powering our fast-paced global sales and marketing timeline,” said Mark Swoboda, Chief Executive Officer of Intematix. “His grasp of lighting business trends and applications and his rapport with our customers and partners will help to seize the opportunities before us.”

Barlow brings over 20 years of marketing, sales and business development leadership in lighting and optoelectronic technology. He has developed and deployed new distribution and sales representative models and has pioneered new applications for LED technology in automotive, consumer and lighting sectors.

“Intematix has a unique opportunity to do something major, to really change the way we approach lighting as an industry,” said Barlow. “Intematix’s technology leadership and growth attracted me, and I’m excited to be a part of their strong executive team. 2012 is going to be a great year for Intematix.”

Intematix’s rapid growth has been supported by expanded facilities in Fremont, California and Suzhou, China. The company’s technology leadership is supported by its broad patent portfolio, including 113 patents issued worldwide and 381 patents pending.

Intematix is exhibiting at the Strategies in Light Conference & Exhibition from February 7-9, 2012 at the Santa Clara Convention Center in Santa Clara, California where their customers’ latest lighting applications are showcased.

About Intematix

Intematix Corporation is a materials development innovator, providing customizable, patented phosphors and phosphor components that serve as the foundation for high quality, energy efficient LED light. Intematix products enable attractive, vivid color quality, superior consistency, uniformity and stability. Headquartered in Fremont, California, Intematix maintains R&D, manufacturing, business and support operations in the United States, Asia and Europe. To learn more about the company, please visit www.intematix.com.

*ChromaLit is a trademark of Intematix Corporation.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50163068&lang=en

IntematixElyssa Thome, 510-933-3300Marketing Communicationselyssa.thome@intematix.com

Source: Intematix Corporation

Cloud-based Email Delivery and Messaging Leader Maintains Focus on Analytics, Reputation Management and Recipient-Centric Deliverability

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- SMTP.com (OTCBB: SMTP) a leading global service provider of cloud-based messaging and email delivery, today introduced an advanced email Suppression tool for its Ecosystem Service Delivery platform.

Email suppression has become a cornerstone technique for high-volume email delivery as it protects individuals from receiving unwanted solicitations and senders from landing on blacklists and irreparably damaging their brands’ online reputation.

“SMTP.com’s Suppression Tool empowers our customers to self-police the quality of their respective contact and mailing lists, which consequently translates into improved delivery and overall campaign results for Senders. Accurate, effective email suppression is an invaluable resource for advertisers, direct and email marketers as it ensures that certain contacts do not receive a specific mailing or communications, which consequently helps senders maintain CAN-SPAM compliance while respecting the privacy and rights of recipients,” commented Semyon Dukach, CEO of SMTP. “SMTP email suppression answers an immediate need from the marketplace, as the lack of an adequate compliance solution can result in significant cost to both brand reputation and balance sheet.”

SMTP is steadfast in its commitment to providing solutions for Recipient-Centric Deliverability. A key value of SMTP’s service is providing 360-degree visibility to the status and results of its customers’ email sending, delivery and recipient feedback to messages. Obtaining feedback on recipient behavior regarding bounces and complaints is critical to maintaining compliant sending practices and brand reputation.

“The most valuable metric for Internet email marketing investment is in effective delivery, which is the core element of SMTP.com’s business and exemplified in this latest offering,” added Mr. Dukach.

At present, SMTP works with customers of all sizes in 150 countries. SMTP, which recently reported a 70% increase in net revenue for Q3 2011, combines technology with expert management, 24-hour availability, service and support to achieve its exceptional standard for customer satisfaction and growth.

ABOUT SMTP, Inc. (OTCBB: SMTP)

SMTP (http://www.SMTP.com) is a leading provider of cloud-based services to facilitate email deliverability, including bulk and transactional sending, reputation management, compliance auditing, abuse processing and issue resolution. Our services provide customers with the ability to increase the deliverability of email with less time, cost and complexity than handling it themselves. SMTP, Inc. is based in Cambridge, Massachusetts and on the web at http://www.smtp.com.

Safe Harbor Statement

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continues," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing new customer offerings, changes in customer order patterns, changes in customer offering mix, continued success in technological advances and delivering technological innovations, delays due to issues with outsourced service providers, and various other factors beyond the Company's control.

For Further Information Contact SMTP, Inc.

JMR WorldwideMostafa Razzak, 212.786.6036m.razzak@jmrworldwide.com

Source: SMTP, Inc.

Intematix recognized for market share leadership and brand equity

FREMONT, Calif.--(BUSINESS WIRE)-- Intematix, a leading innovator of patented phosphors and phosphor components for high-quality LED lighting, was named the number one phosphor supplier in China in 2011, according to respected LED market research company Gaogong LED. Intematix was also named one of the seven most recognizable LED lighting brands by the China National Semiconductor Lighting Association, alongside some of the largest global component and production equipment brands in the LED industry. These accolades highlight Intematix’s position as the top phosphor company in China.

“Intematix has built its phosphor leadership in the Chinese LED market by offering extensive product choice and working closely with our customers,” said Yiqun Li, Chief Technology Officer and Executive Vice President at Intematix. “We look forward to 2012 as the LED market in China continues to grow.”

According to Gaogong’s statistics, China produced 32 billion yuan ($5.1 billion) in packaged LEDs in 2011, more than a third of the global total and at an annual growth rate of 18%.

Intematix has expanded its diverse product offering in the last year with 14 new phosphor products and its remote phosphor product line, ChromaLit™. Intematix supplies many of China’s leading manufacturers, and its global production and certified quality system enabled its significant market share. Intematix opened its new 124,000 square foot facility in Suzhou, China, significantly increasing the company’s Chinese manufacturing presence, and Intematix’s Shenzhen-based office helped strengthen its reputation in China by providing comprehensive sales and applications support to customers. As China continues to grow as an LED manufacturing and applications powerhouse, Intematix has positioned itself to great advantage.

About Intematix

Intematix Corporation is a materials development innovator, providing customizable, patented phosphors and phosphor components that serve as the foundation for high quality, energy efficient LED light. Intematix products enable attractive, vivid color quality, superior consistency, uniformity, and stability. Headquartered in Fremont, California, Intematix maintains R&D, manufacturing, business and support operations in the United States, Asia and Europe. To learn more about the company, please visit www.intematix.com.

*ChromaLit is a trademark of Intematix Corporation.

Marketing CommunicationsElyssa Thome, 510-933-3300elyssa.thome@intematix.comintematix@antennagroup.comorGrayling Connecting Point for IntematixDeanna Siste, 415-442-4020deanna.siste@graylingcp.com

Source: Intematix Corporation